Not finding it? Sign in to also search OpenAlex live.
-
406 Prognostic relevance of the molecular endometrial cancer classification among patients staged by lymphadenectomy and/or without adjuvant treatment2021 Endometrial cancer conference-paper Medicine Endometrial and Cervical Cancer Treatments Open access
Alicia León‐Castillo, Nanda Horeweg, Elke E.M. Peters, Tessa A. Rutten, Natalja T. ter Haar, Vincent T.H.B.M. Smit, +7 more
1citations -
482 Tertiary lymphoid structures as markers of anti-tumor immunity with independent prognostic value in the PORTEC-3 trial of high-risk endometrial cancer2021 International Journal of Gynecological Cancer article Medicine Endometrial and Cervical Cancer Treatments Open access
Nanda Horeweg, Hagma H. Workel, Dominik Loiero, David N. Church, Lisa Vermij, Alicia León‐Castillo, +13 more
0citations -
417 Does serous tubal intraepithelial carcinoma metastasize? The clonal relationship between serous tubal intraepithelial carcinoma and subsequent high-grade serous carcinoma in BRCA1/2 germline pathogenic varient carriers several years after risk-reducing salpingo-ophorectomy2024 International Journal of Gynecological Cancer article Biochemistry, Genetics and Molecular Biology BRCA gene mutations in cancer Open access
Caroline BVan Den Berg, Shatavisha Dasgupta, Patricia C. Ewing‐Graham, Joost Bart, Hans Bulten, Katja N. Gaarenstroom, +6 more
0citations -
1013 Progression from NSMP to p53-abnormal Endometrial Carcinoma: Introducing Class-Switching in the Molecular Classification2025 Laboratory Investigation article Medicine Endometrial and Cervical Cancer Treatments Open access
Claire J.H. Kramer, Nanda Horeweg, Dina Ruano, Gitte Lykkegaard, Estrid Vilma Solyom Høgdall, Cor Doede de Kroon, +8 more
0citations -
Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner Drouet, Lutz Peter Mueller, Christoph Schmid, +30 more
0citations -
Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Laurien Joanna Zeverijn, Eleonora J. Looze, Subotheni Thavaneswaran, Jade M. van Berge Henegouwen, John R. Simes, Louisa Rose Hoes, +14 more
4citations -
Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study2021 JNCI Journal of the National Cancer Institute article Biochemistry, Genetics and Molecular Biology BRCA gene mutations in cancer Open access
Marthe M. de Jonge, Cor Doede de Kroon, Denise J. Jenner, Jan Oosting, Joanne A. de Hullu, Marian J.E. Mourits, +12 more
94citations -
BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis2022 Future Oncology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access cited by 1 patent
Srđan Verstovšek, Haifa Kathrin Al‐Ali, John O Mascarenhas, Andrew Charles Perkins, Alessandro Maria Vannucchi, Sanjay Ram Mohan, +8 more
40citations -
The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer2021 Frontiers in Oncology article Biochemistry, Genetics and Molecular Biology RNA Research and Splicing Open access cited by 1 patent
Alexander C. Leeksma, Ingrid A. M. Derks, M. Haidar Kasem, Emine Kılıç, Annelies de Klein, Martine Johanna Jager, +11 more
21citations -
Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial
Natalia Tovar, Valentín Ortiz‐Maldonado, Núria Martínez‐Cibrián, Sergi Betriu, Daniel Esteban, Ana Triguero, +5 more
5citations -
Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1-Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients
Marius Bill, Jan‐Niklas Eckardt, Christian R. Rausch, Klaus Hans Metzeler, Karsten Spiekermann, Sebastian Stasik, +34 more
3citations -
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort
Marie José Kersten, Joost S.P. Vermaat, Pim G. N. J. Mutsaers, Maria Theresa Kuipers, Évelyne Willems, Sébastien Anguille, +14 more
3citations